PeopleBeatingCancer

Our Mission

PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.

Click the orange button to the right to learn more.

Learn More

Fenbendazole and Gastrointestinal (stomach) Cancer

Share Button

Fenbendazole and Gastrointestinal (stomach) Cancer: What the Research Really Shows. Fenbendazole (fenben), a veterinary anti-parasitic drug, has gained attention online as a potential repurposed cancer therapy. While anecdotal reports are common, the real question is:

What does the science actually show—especially for gastrointestinal cancers such as colorectal, gastric, and pancreatic cancer?

This article reviews the mechanisms, available evidence, limitations, and risks of fenbendazole in GI cancers.

I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths and taken great risks in an effort to manage my blood cancer.  I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.

The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and cancer debate. Please scroll down the page, post a question or a comment if you have any questions.

If you’d like to learn more about repurposed drugs and cancer treatment, click now. 

Thank you,

David Emerson

To Learn More About Repurposed Drugs for Cancer-

How Fenbendazole Could Treat Cancer (and Why It Might Not)

What Is Fenbendazole?

Fenbendazole is a benzimidazole anti-parasitic drug widely used in animals to treat intestinal parasites. It is:

  • Not FDA-approved for human use
  • Structurally related to mebendazole, a similar drug studied in cancer

Despite growing interest, major organizations emphasize:

Evidence in humans is still very limited and early

How Fenbendazole May Work Against Cancer

Preclinical research (lab and animal studies) suggests several anti-cancer mechanisms:

1. Microtubule Disruption

Fenbendazole binds to tubulin, disrupting microtubules required for cancer cell division.

2. Induction of Apoptosis

Studies show that fenbendazole can trigger programmed cancer cell death and cell cycle arrest.

3. Metabolic Interference

Fenbendazole may:

  • Reduce glucose uptake
  • Increase oxidative stress
  • Disrupt cancer metabolism

These effects may “starve” tumor cells.

4. Multi-Pathway Activity

Benzimidazole drugs affect multiple cancer pathways simultaneously, including:

  • Cell cycle regulation
  • Angiogenesis
  • Stress signaling

Evidence in Gastrointestinal Cancers

Unlike some other cancer types, there is limited but relevant preclinical evidence in GI cancers.

Colorectal Cancer

  • Fenbendazole has demonstrated anti-tumor effects in colorectal cancer cell lines, including drug-resistant cells
  • It induces:
    • Apoptosis
    • Cell cycle arrest
    • Ferroptosis-related pathways

👉 This is one of the strongest areas of direct evidence.

Gastric (Stomach) Cancer

  • Recent studies suggest that fenbendazole can trigger pyroptosis (inflammatory cancer cell death) in gastric cancer pathways
  • This involves activation of caspase-3 and GSDME signaling

👉 This is early but biologically meaningful research.

Pancreatic Cancer

  • Research is limited, but early findings suggest:
    • Possible inhibition of tumor growth
    • Disruption of microtubule
  • However, no clinical trials exist, and evidence remains preliminary

General GI Cancer Insight

A broader study found fenbendazole:

  • Inhibits the proliferation of colon cancer cells (HCT116)
  • Shows selective toxicity toward cancer cells vs. normal cells

What the Research Actually Shows (Big Picture)

Positive Signals

  • Anti-cancer activity in:
    • Colorectal cancer cells
    • Gastric cancer pathways
    • Multiple tumor models
  • Activity in chemotherapy-resistant cancer cells

Limitations

  • Evidence is almost entirely preclinical
  • No randomized human trials
  • Poor bioavailability may limit effectiveness

Even comprehensive reviews conclude:

Clinical evidence supporting fenbendazole in cancer is limited

Negative or Contradictory Findings

  • Some studies found no meaningful anti-tumor effect
  • Earlier research concluded it did not justify further development as a cancer therapy

Human Evidence: What Do We Know?

  • Limited to case reports and anecdotal use
  • No controlled trials in GI cancers
  • Outcomes are inconsistent and confounded

Experts warn:

Lab success does not translate reliably to human benefit

Risks and Safety Concerns

This is a critical issue.

Fenbendazole:

  • Is not approved for human use
  • Has unknown dosing and pharmacokinetics
  • Has been linked to:
    • Liver toxicity
    • Potential drug interactions

There are also concerns that:

  • It may act as a tumor promoter in certain conditions

Fenbendazole vs. Standard GI Cancer Treatments

Gastrointestinal cancers are typically treated with:

  • Surgery
  • Chemotherapy (e.g., FOLFOX, FOLFIRI)
  • Targeted therapy
  • Immunotherapy

These treatments are supported by large clinical trials and have improved survival across GI cancers.

👉 Replacing or delaying these therapies with fenbendazole could significantly reduce survival chances.

Integrative, Evidence-Based Alternatives

Instead of relying on unproven therapies, research supports:

1. Nutrition

  • High-fiber diets (colorectal cancer)
  • Anti-inflammatory diets

2. Exercise

  • Improves survival and treatment tolerance

3. Gut Microbiome Support

  • Increasingly important in GI cancers

4. Evidence-Based Supplements (with MD guidance)

  • Omega-3 fatty acids
  • Curcumin
  • Vitamin D

These approaches have human clinical data, unlike fenbendazole.

Key Takeaway

Fenbendazole shows biological activity in gastrointestinal cancers—but only in laboratory settings.

Bottom Line

What We Know

  • Fenbendazole has anti-cancer effects in:
    • Colorectal cancer cells
    • Gastric cancer pathways
  • It targets multiple mechanisms

What We Don’t Know

  • Whether it works in humans
  • Whether it improves survival
  • Safe and effective dosing

What Patients Should Understand

Fenbendazole is experimental and unproven for gastrointestinal cancers.

Final Thought

Fenbendazole is a promising research candidate, but not a validated therapy.

For patients with GI cancers:

  • Prioritize evidence-based treatments
  • Use integrative therapies to support—not replace—standard care

To Learn More About Repurposed Drugs for Cancer-

References

Leave a Comment:

Popular posts

Multiple Myeloma Diet
 Multiple Myeloma Multiple Myeloma Diet
Feb 15, 2022
Multiple Myeloma Second Opinion: 7 Questions Every Newly Diagnosed Patient Should Ask
 Multiple Myeloma
Nov 04, 2022
C-B-D Enhances Velcade (BORT)
 integrative therapy Multiple Myeloma
Aug 07, 2022
Can Endometrial Polyps Become Cancer? What Women Need to Know
 Endometrial Cancer
Nov 14, 2021